10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
9.16
-0.25 (-2.66%)
At close: Mar 28, 2025, 4:00 PM
9.00
-0.16 (-1.75%)
After-hours: Mar 28, 2025, 7:20 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for 10x Genomics stock have an average target of 20, with a low estimate of 12 and a high estimate of 32. The average target predicts an increase of 118.34% from the current stock price of 9.16.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 7 | 7 | 7 | 7 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 16 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +63.76% | Mar 4, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $28 → $26 | Buy | Maintains | $28 → $26 | +183.84% | Feb 14, 2025 |
| Barclays | Barclays | Buy Maintains $18 → $15 | Buy | Maintains | $18 → $15 | +63.76% | Feb 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | +96.51% | Feb 13, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +118.34% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
619.49M
from 610.79M
Increased by 1.43%
Revenue Next Year
674.36M
from 619.49M
Increased by 8.86%
EPS This Year
-1.50
from -1.52
EPS Next Year
-1.15
from -1.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 658.5M | 721.7M | 810.5M | ||
| Avg | 619.5M | 674.4M | 734.8M | ||
| Low | 587.6M | 633.5M | 668.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.8% | 16.5% | 20.2% | ||
| Avg | 1.4% | 8.9% | 9.0% | ||
| Low | -3.8% | 2.3% | -0.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.20 | -0.17 | -0.30 | ||
| Avg | -1.50 | -1.15 | -0.85 | ||
| Low | -1.81 | -1.71 | -1.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.